alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Sent: Thursday, December 08, 2011 10:54:25 AM 

To: Shebik, Ronald; Raymond, Michael; AS_Waiver_Requests; 

Armstrong, Ashley; Llenza, Charles 

Subject: RE: Petition for Waiver and Application for Interim Waiver - Hussmann Bulk Produce Cases 

Auto forwarded by a Rule

One additional note – the notice to other manufacturers was sent Robert Weeks of Kysor/Warren and 

Larry Howington of Hill Phoenix. The names of these individuals differ from what is on the application.

However, these individuals deal directly with compliance to DOE and understand the laws and 

requirements.

Thank you,

Ron Shebik

Regulatory Compliance Manager

Hussmann Corporation

12999 St. Charles Rock Road

Bridgeton, MO 63044

314.298.6483

ron_shebik@hussmann.com

From: Shebik, Ronald 

Sent: Wednesday, December 07, 2011 5:26 PM

To: 'Michael.Raymond@ee.doe.gov'; 'AS_Waiver_Requests@ee.doe.gov'; 'Armstrong, Ashley'; 'Llenza, 

Charles'

Subject: RE: Petition for Waiver and Application for Interim Waiver - Hussmann Bulk Produce Cases 

Mr. Raymond, Ms. Armstrong, Mr. Llenza

I also included a pdf of the signed copies.

Thank you,

Ron Shebik

Regulatory Compliance Manager

Hussmann Corporation

12999 St. Charles Rock Road

Bridgeton, MO 63044

314.298.6483

ron_shebik@hussmann.com

From: Shebik, Ronald 

Sent: Wednesday, December 07, 2011 5:13 PM
To: 'Michael.Raymond@ee.doe.gov'; 'AS_Waiver_Requests@ee.doe.gov'; 'Armstrong, Ashley'; Llenza, 

Charles

Subject: Petition for Waiver and Application for Interim Waiver - Hussmann Bulk Produce Cases 

Mr. Raymond, Ms. Armstrong, Mr. Llenza

I have attached the Petition for Waiver and Application for Interim Waiver documents. Please let me 

know if you have any questions or any further action is needed.

Thank you,

Ron Shebik

Regulatory Compliance Manager

Hussmann Corporation

12999 St. Charles Rock Road

Bridgeton, MO 63044

314.298.6483

ron_shebik@hussmann.com

The information contained in this message is privileged and intended only for the recipients named. If the reader is not a representative of the 

intended recipient, any review, dissemination or copying of this message or the information it contains is prohibited. If you have received this 

message in error, please immediately notify the sender, and delete the original message and attachments.
```

[Congressional Bills 112th Congress]
[From the U.S. Government Publishing Office]
[S. 31 Introduced in Senate (IS)]

112th CONGRESS
  1st Session
                                 S. 31

To amend part D of title XVIII of the Social Security Act to authorize 
   the Secretary of Health and Human Services to negotiate for lower 
                prices for Medicare prescription drugs.

_______________________________________________________________________

                   IN THE SENATE OF THE UNITED STATES

             January 25 (legislative day, January 5), 2011

  Mr. Franken introduced the following bill; which was read twice and 
                  referred to the Committee on Finance

_______________________________________________________________________

                                 A BILL

 
To amend part D of title XVIII of the Social Security Act to authorize 
   the Secretary of Health and Human Services to negotiate for lower 
                prices for Medicare prescription drugs.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Prescription Drug and Health 
Improvement Act of 2011''.

SEC. 2. NEGOTIATING FAIR PRICES FOR MEDICARE PRESCRIPTION DRUGS.

    (a) Negotiating Fair Prices.--
            (1) In general.--Section 1860D-11 of the Social Security 
        Act (42 U.S.C. 1395w-111) is amended by striking subsection (i) 
        (relating to noninterference) and by inserting the following:
    ``(i) Authority To Negotiate Prices With Manufacturers.--In order 
to ensure that beneficiaries enrolled under prescription drug plans and 
MA-PD plans pay the lowest possible price, the Secretary shall have 
authority similar to that of other Federal entities that purchase 
prescription drugs in bulk to negotiate contracts with manufacturers of 
covered part D drugs, consistent with the requirements and in 
furtherance of the goals of providing quality care and containing costs 
under this part.''.
            (2) Effective date.--The amendment made by paragraph (1) 
        shall take effect on the date of the enactment of this Act.
    (b) Biannual Reports to Congress.--Not later than 1 year after the 
date of the enactment of this Act, and every 6 months thereafter, the 
Secretary of Health and Human Services shall submit to Congress a 
report on the negotiations conducted by the Secretary under section 
1860D-11(i) of the Social Security Act (42 U.S.C. 1395w-111(i)), as 
amended by subsection (a), including a description of how such 
negotiations are achieving lower prices for covered part D drugs (as 
defined in section 1860D-2(e) of the Social Security Act (42 U.S.C. 
1395w-102(e)) for Medicare beneficiaries.
                                 <all>
```
Early HARRIS, III, Appellant, v. Tanya Michelle HARRIS, Appellee.

Case No. 5D17-792

District Court of Appeal of Florida, Fifth District.

Opinion filed March 29, 2018 Rehearing Denied May 2, 2018

Angela Lynn Leiner, of The Law Office of Angela L. Leiner, P.A., St. Petersburg, for Appellant.

John J. Albert, of Albert & Donnelly, LLC, Melbourne, for Appellee.

PER CURIAM.

AFFIRMED. *See**Tramble v. Tramble* , 193 So.3d 1105, 1105 (Fla. 5th DCA 2016) (holding that in absence of transcript or statement of evidence, appellate court's review is limited to errors appearing on face of final judgment or in pleadings and other matters in record); *Spreng v. Spreng* , 162 So.3d 168, 169 (Fla. 5th DCA 2015) (holding that although trial court's order awarding wife attorney's fees was deficient in its factual findings, error was not preserved for appeal because husband never filed motion for rehearing); *Hedstrom v. Hedstrom* , 123 So.3d 150, 152 n.4 (Fla. 5th DCA 2013) (reiterating that party cannot complain on appeal about inadequate findings unless alleged defect was brought to trial court's attention in motion for rehearing).

SAWAYA, EVANDER and EISNAUGLE, JJ., concur.
----

| ·   | Base      Salary: $110,000 |
|--------------------|----------------------------|

| ·   | Performance      and salary reviews will take place annually on your      anniversary |
|--------------------|---------------------------------------------------------------------------------------|

| ·   | Performance      compensation: You will receive 1.5% of the first $1.5M of the gross sales      of Rivex, and 1% on the next $1M      gross sales. This performance compensation will be paid to you on a      regular basis throughout the year, probably  quarterly |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | Share      options: you will receive 75,000 share options of Helix BioPharma Corp. on      joining our group, at the option price of approximately $2.00 (The option      price is presently under discussion with the hope of having it      lowered) |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | Additional      share options may be available in the future, and you will receive options      in this same proportion to options being received by other senior      management |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | Monthly      car allowance: $500. This is subject to future review. The Company will      also provide a credit card |
|--------------------|----------------------------------------------------------------------------------------------------------------------|

| ·   | You      will be immediately eligible for enrollment in the Company's standard      benefits program |
|--------------------|------------------------------------------------------------------------------------------------------|

----

| ·   | Vacation:      4 weeks annually |
|--------------------|---------------------------------|

| ·   | Should      your employment be terminated for reasons other than just cause, you will      be given 9 months written notice, or payment equal to 9 months      salary |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | Start      date: August 25 or earlier |
|--------------------|---------------------------------------|
EXHIBIT 32.1

                            SECTION 906 CERTIFICATION






<PAGE>




                                  Exhibit 32.1

                     CERTIFICATION OF DISCLOSURE PURSUANT TO
                             18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002


In connection with the Annual Report of Navidec  Financial  Services,  Inc. (the
"Company") on Form 10-KSB for the period ending  December 31, 2006 as filed with
the Securities and Exchange Commission on the date hereof (the "Report") I, John
R. McKowen,  Chief  Executive  Officer and Chairman of the Board of the Company,
certify,  pursuant to 18 USC section 1350, as adopted pursuant to section 906 of
the Sarbanes-Oxley Act of 2002, that to the best of my knowledge and belief:

         (1) The Report fully complies with the requirements of Section 13(a) or
15(d) of the Securities Exchange Act of 1934; and

         (2) The  information  contained in the Report fairly  presents,  in all
material  respects,  the  financial  condition  and results of operations of the
Company.


Dated: May 1, 2007

/s/John R. McKowen
------------------------------------------------------------------
John R. McKowen, Chief Executive Officer and Chairman of the Board


This  certification  accompanies  the  Report  pursuant  to  Section  906 of the
Sarbanes-Oxley  Act of 2002 and shall not,  except to the extent required by the
Sarbanes-Oxley  Act of 2002,  be deemed  filed by the  Company  for  purposes of
Section 18 of the Securities Exchange Act of 1934, as amended.
II 

112TH CONGRESS 

2D SESSION S. 2592 

To extend the temporary suspension of duty on staple fibers of viscose 

rayon, not carded, combed, or otherwise processed for spinning. 

IN THE SENATE OF THE UNITED STATES 

MAY 7, 2012 

Mr. CARPER (for himself and Mr. COONS) introduced the following bill; which 

was read twice and referred to the Committee on Finance 

A BILL 

To extend the temporary suspension of duty on staple fibers 

of viscose rayon, not carded, combed, or otherwise processed for spinning. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. STAPLE FIBERS OF VISCOSE RAYON, NOT 

4 CARDED, COMBED, OR OTHERWISE PROC5 ESSED FOR SPINNING. 

6 (a) IN GENERAL.—Heading 9902.23.33 of the Har7 monized Tariff Schedule of the United States (relating to 

8 staple fibers of viscose rayon, not carded, combed, or oth9 erwise processed for spinning) is amended by striking the 


srobinson on DSK4SPTVN1PROD with BILLS
2 

•S 2592 IS

1 date in the effective period column and inserting ‘‘12/31/ 

2 2015’’. 

3 (b) EFFECTIVE DATE.—The amendments made by 

4 subsection (a) apply with respect to goods entered, or 

5 withdrawn from warehouse for consumption, on or after 

6 the 15th day after the date of the enactment of this Act. 

Æ 


srobinson on DSK4SPTVN1PROD with BILLS
Ayman NEKHAILA, Appellant, v. The STATE of Florida, Appellee.

No. 3D17-1530

District Court of Appeal of Florida, Third District.

Opinion filed February 7, 2018.

**DECISION WITHOUT PUBLISHED OPINION**

Affirmed.
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS, STATEMENTS OF OPERATIONS
AND STATEMENTS OF CASH FLOWS AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE
TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
       
<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-1997
<PERIOD-END>                               SEP-28-1997
<CASH>                                         100,000
<SECURITIES>                                         0
<RECEIVABLES>                                8,221,000
<ALLOWANCES>                                         0
<INVENTORY>                                 14,945,000
<CURRENT-ASSETS>                            24,287,000
<PP&E>                                      17,687,000
<DEPRECIATION>                               7,837,000
<TOTAL-ASSETS>                              35,756,000
<CURRENT-LIABILITIES>                        5,120,000
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                        68,000
<OTHER-SE>                                  19,630,000
<TOTAL-LIABILITY-AND-EQUITY>                35,756,000
<SALES>                                     29,360,000
<TOTAL-REVENUES>                            29,360,000
<CGS>                                       22,354,000
<TOTAL-COSTS>                               27,860,000
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                             578,000
<INCOME-PRETAX>                                922,000
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                          1,522,000
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                 1,522,000
<EPS-PRIMARY>                                      .26
<EPS-DILUTED>                                      .26
        

</TABLE>
precoptics_ex1004.htm


 







EXHIBIT 10.4


 


ENDORSEMENT TO 10% SENIOR SECURED CONVERTIBLE NOTE


 


Precision Optics Corporation, Inc.


New York, New York


October 31, 2011


 


The 10% Senior Secured Convertible Note dated June 25, 2008 and amended December 11, 2008, June 25, 2010, July 26, 2010, September 15, 2010, October 15, 2010, November 15, 2010, November 30, 2010, December 1, 2010, December 3, 2010 and December 17, 2010, January 10, 2011, January 24, 2011, February 7, 2011,  February 25, 2011,  March 11, 2011, March 31, 2011, April 15, 2011, April 29, 2011, May 13, 2011, June 3, 2011, June 28, 2011, July 6, 2011, July 20, 2011, July 25, 2011, July 27, 2011, August 31, 2011, and September 30, 2011  (the “Note”) of Precision Optics Corporation, Inc., a Massachusetts corporation (the “Company”), payable to the order of Arnold Schumsky (the “Holder”) in an aggregate principal amount of $50,000 and to which this Endorsement is affixed is hereby amended in the following respects:


 




	 	
1.

	
 The term “Stated Maturity Date” is hereby restated to be “December 15, 2011.”


	 	  	  
	 	
2.

	
 Except as expressly amended by this Endorsement, the Note remains in full force and effect and the Company hereby reconfirms its obligations thereunder.









 


IN WITNESS WHEREOF, the Company has caused this Endorsement to be duly executed, and the Holder has caused this Endorsement to be duly accepted, by their respective duly authorized representatives as of the day and year first above written.


 


 



	  	
PRECISION OPTICS CORPORATION, INC.


	  	  
	  	
By

	
/s/ Joseph N. Forkey


	  	  	  
	  	  	
Name: Joseph N. Forkey


	  	  	
Title: Chief Executive Officer







 



	
Accepted:

	  
	  	  
	  	  
	
/s/ Arnold Schumsky 

	  
	  	  
	
Arnold Schumsky
<TABLE>
<CAPTION>

   Schedule of Year-To-Date Principal and Interest Distributions
                           to
                  Certificateholders

                                                                     Ending
Class         Interest        Principal           Losses            Balance
<S>             <C>              <C>                <C>               <C>
A1           8649178.27      12859545.85                0      1647782683.31
A2           1417167.19       2406413.17                0       269689689.16
A3            360918.69        237254.57                0        69059135.61
APO                   0         73529.77                0         9423601.35
AR               510.84              100                0                  0
B1             86800.95         57059.73                0        16608722.12
B2             37968.66         24959.18                0         7265021.07
B3             37968.66         24959.18                0         7265021.07
B4             21727.32         14282.74                0         4157359.96
B5             16241.34         10676.45                0         3107661.09
B6             16308.97          9494.76          1226.14         3120599.68


</TABLE>
### TEXA S C OU R T OF A PPEAL S, THIR D DIST R ICT , AT AU STIN NO. 03-06-00334- CV Liz be th He r nande z , A ppe lla nt

v. Travis County, Texas, App ellee F ROM COUNTY COURT AT LAW NO. 1 OF TRAVIS COUNTY NO. 281,12 9, HO NORAB LE ORLINDA NARANJO , JUDGE PRESIDI NG

M E M O R

A N D UM O P I N I ON Appellant L izbeth He rnande z has notified us that the parties have sig ned a se ttlement agree ment and moves to dismiss her appea l. We gr ant the motion and dismiss t he appe al. SeeT e x. R. App. P. 42.1(a).

W. Kenneth L aw, Chief Justice Be fore Chief J ustice L aw, Justi ces Pembe rton, Waldrop Dismissed on Appellant’s Motion Filed: August 9, 2006
---

Exhibit 13.2



CERTIFICATIONS



CERTIFICATION PURSUANT TO

18 U.S.C. §1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002



In connection with the Annual Report of Forbes Medi-Tech Inc. (the Company) on Form 20-F for the period ended December 31, 2007 as filed with the Securities and Exchange Commission on the date hereof (the Report), I, David Goold, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:



(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and



(2)

The information contained in this Report fairly presents, in all material respects, the financial condition and results of operations of the Company.



|                      |  |     |  |                                                                                                                              
|--------------------- |  | --- |  | -----------------------------------------------------------------------------------------------------------------------------
|                      |  |     |  |                                                                                                                              
|Date:  March 31, 2008 |  | By: |  | /s/ David Goold
        
      David Goold
        Chief Financial Officer
      (Principal Financial and Accounting Officer)



A signed original of this written statement required by Section 906 has been provided to Forbes Medi-Tech Inc. and will be retained by Forbes Medi-Tech Inc. and furnished to the Securities and Exchange Commission or its staff upon request.



---
II 

112TH CONGRESS 

2D SESSION S. 2639 

To suspend temporarily the duty on bisphenol A Bis(3- 

methacryloyloxypropyl)ether substituted dimethacylate. 

IN THE SENATE OF THE UNITED STATES 

MAY 7, 2012 

Ms. KLOBUCHAR introduced the following bill; which was read twice and 

referred to the Committee on Finance 

A BILL 

To suspend temporarily the duty on bisphenol A Bis(3- 

methacryloyloxypropyl)ether substituted dimethacylate. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. BISPHENOL A BIS(3- 

4 METHACRYLOYLOXYPROPYL)ETHER SUB5 STITUTED DIMETHACYLATE. 

6 (a) IN GENERAL.—Subchapter II of chapter 99 of 

7 the Harmonized Tariff Schedule of the United States is 

8 amended by inserting in numerical sequence the following 

9 new heading: 


tjames on DSK6SPTVN1PROD with BILLS
2 

•S 2639 IS

‘‘ 9902.01.00 Bisphenol A Bis(3- 

methacryloyloxypropyl)ether 

substituted dimethacylate 

(CAS No. 27689–12–9) (provided for in subheading 

2916.14.20) ........................... Free No change No change On or before 

12/31/2015 ’’. 

1 (b) EFFECTIVE DATE.—The amendment made by 

2 subsection (a) applies with respect to goods entered, or 

3 withdrawn from warehouse for consumption, on or after 

4 the 15th day after the date of the enactment of this Act. 

Æ 


tjames on DSK6SPTVN1PROD with BILLS
II 

112TH CONGRESS 

2D SESSION S. 3034 

To extend the temporary suspension of duty on Linuron. 

IN THE SENATE OF THE UNITED STATES 

MAY 9, 2012 

Ms. CANTWELL introduced the following bill; which was read twice and 

referred to the Committee on Finance 

A BILL 

To extend the temporary suspension of duty on Linuron. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. LINURON. 

4 (a) IN GENERAL.—Heading 9902.13.24 of the Har5 monized Tariff Schedule of the United States (relating to 

6 Linuron) is amended by striking the date in the effective 

7 period column and inserting ‘‘12/31/2015’’. 

8 (b) EFFECTIVE DATE.—The amendments made by 

9 subsection (a) apply to goods entered, or withdrawn from 

10 warehouse for consumption, on or after the 15th day after 

11 the date of the enactment of this Act. 

Æ 


jbell on DSK7SPTVN1PROD with BILLS
II 

112TH CONGRESS 

2D SESSION S. 3104 

To extend the temporary suspension of duty on acid blue 324. 

IN THE SENATE OF THE UNITED STATES 

MAY 10, 2012 

Mrs. HAGAN introduced the following bill; which was read twice and referred 

to the Committee on Finance 

A BILL 

To extend the temporary suspension of duty on acid blue 

324. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. ACID BLUE 324. 

4 (a) IN GENERAL.—Heading 9902.25.02 of the Har5 monized Tariff Schedule of the United States (relating to 

6 acid blue 324) is amended by striking the date in the effec7 tive period column and inserting ‘‘12/31/2015’’. 

8 (b) EFFECTIVE DATE.—The amendment made by 

9 subsection (a) applies to goods entered, or withdrawn from 


srobinson on DSK4SPTVN1PROD with BILLS
2 

•S 3104 IS

1 warehouse for consumption, on or after the 15th day after 

2 the date of the enactment of this Act. 

Æ 


srobinson on DSK4SPTVN1PROD with BILLS